FR16C1001I1 - "Dérivé de 2-oxo-1-pyrrolidine et ses applications pharmaceutique" - Google Patents

"Dérivé de 2-oxo-1-pyrrolidine et ses applications pharmaceutique"

Info

Publication number
FR16C1001I1
FR16C1001I1 FR16C1001C FR16C1001I1 FR 16C1001 I1 FR16C1001 I1 FR 16C1001I1 FR 16C1001 C FR16C1001 C FR 16C1001C FR 16C1001 I1 FR16C1001 I1 FR 16C1001I1
Authority
FR
France
Prior art keywords
sup
oxo
pharmaceutical applications
pyrrolidine derivative
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9886259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C1001(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of FR16C1001I1 publication Critical patent/FR16C1001I1/fr
Application granted granted Critical
Publication of FR16C1001I2 publication Critical patent/FR16C1001I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
FR16C1001C 2000-02-23 2016-05-25 "derive de 2-oxo-1-pyrrolidine et ses applications pharmaceutiques" Active FR16C1001I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0004297.8A GB0004297D0 (en) 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP01925354A EP1265862B1 (fr) 2000-02-23 2001-02-21 Derives de 2-oxo-1-pyrrolidine, procedes de preparation et utilisations desdits derives

Publications (2)

Publication Number Publication Date
FR16C1001I1 true FR16C1001I1 (fr) 2016-07-01
FR16C1001I2 FR16C1001I2 (fr) 2017-02-03

Family

ID=9886259

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C1001C Active FR16C1001I2 (fr) 2000-02-23 2016-05-25 "derive de 2-oxo-1-pyrrolidine et ses applications pharmaceutiques"

Country Status (43)

Country Link
US (12) US6713635B2 (fr)
EP (8) EP1577296A1 (fr)
JP (5) JP4121744B2 (fr)
KR (4) KR100816185B1 (fr)
CN (5) CN1303066C (fr)
AT (5) ATE282592T1 (fr)
AU (5) AU5214401A (fr)
BE (1) BE2016C012I2 (fr)
BG (4) BG65923B1 (fr)
BR (2) BRPI0108664B8 (fr)
CA (2) CA2401033C (fr)
CO (2) CO5280059A1 (fr)
CU (2) CU23293B7 (fr)
CY (3) CY1105517T1 (fr)
CZ (3) CZ304702B6 (fr)
DE (5) DE60113514T2 (fr)
DK (3) DK1447399T3 (fr)
EG (1) EG24375A (fr)
ES (5) ES2355140T3 (fr)
FR (1) FR16C1001I2 (fr)
GB (1) GB0004297D0 (fr)
HK (2) HK1052516B (fr)
HU (4) HU229514B1 (fr)
IL (5) IL150757A0 (fr)
IS (8) IS2119B (fr)
LT (1) LTC1265862I2 (fr)
LU (1) LU92993I2 (fr)
ME (1) ME00595B (fr)
MX (2) MXPA02008056A (fr)
MY (4) MY138966A (fr)
NL (1) NL300815I2 (fr)
NO (6) NO324051B1 (fr)
NZ (1) NZ520448A (fr)
PL (3) PL212197B1 (fr)
PT (2) PT1452524E (fr)
RO (2) RO121597B1 (fr)
RS (2) RS50455B (fr)
RU (5) RU2355680C2 (fr)
SA (2) SA01220027B1 (fr)
SI (1) SI1265862T1 (fr)
TW (2) TW200626545A (fr)
WO (2) WO2001062726A2 (fr)
ZA (2) ZA200205671B (fr)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365093B2 (en) * 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
JP2004523557A (ja) * 2001-02-23 2004-08-05 ジョンズ・ホプキンス・ユニバーシティ チック、振せん、および関連疾患の治療
ATE410412T1 (de) 2001-08-10 2008-10-15 Ucb Pharma Sa Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
CA2461961A1 (fr) * 2001-10-08 2003-04-17 Ucb, S.A. Utilisation de derives de 2-oxo-1-pyrrolidine pour la preparation d'un medicament
CN1604776A (zh) 2001-10-16 2005-04-06 记忆药物公司 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
AU2003242538A1 (en) * 2002-05-14 2003-11-11 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
AU2004204338A1 (en) * 2003-01-13 2004-07-29 Ucb Hydrogenation catalysts
EP1517893A2 (fr) * 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Procede de production de levetiracetam
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
TR200503397T1 (tr) * 2003-03-18 2007-03-21 Hetero Drugs Limited Levetirasetam'ın yeni kristal formları.
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
SG169900A1 (en) 2003-04-16 2011-04-29 Memory Pharm Corp 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
EP1663968A1 (fr) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Procede de preparation de levetiracetam pur
US7629474B2 (en) * 2003-09-24 2009-12-08 Ucb Pharma S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives
BRPI0417157A (pt) * 2003-12-02 2007-03-06 Ucb Sa composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
KR101159870B1 (ko) 2004-06-11 2012-06-25 유씨비 소시에떼아노님 분자내 알릴화에 의해 2-옥소-1-피롤리딘 유도체를제조하는 방법
EP1831154B1 (fr) * 2004-06-21 2010-01-13 Warner-Lambert Company LLC Preparation de composes associes a la pregabaline
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006044955A1 (fr) * 2004-10-20 2006-04-27 Memory Pharmaceuticals Corporation Inhibiteurs de la phosphodiéstérase 4
CA2488325C (fr) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Methode de synthese amelioree du (s)-alpha-ethyl-2-oxo-1-pyrrolidine-acetamide et du (r)-alpha-ethyl-2-oxo-1-pyrroldine-acetamide
CA2610695A1 (fr) 2005-06-01 2006-12-07 Ucb Pharma, S.A. Derives de 2-oxo-1-pyrrolidine
EP1731149A1 (fr) * 2005-06-08 2006-12-13 Ucb S.A. Utilisation de Brivaracetam pour le traitement de maladies caracterisées par l'épilepsie myoclonique progressive
MY143249A (en) * 2005-09-15 2011-04-15 Ucb Pharma Sa 4-substituted pyrrolidin-2-ones and their use
JP2007153755A (ja) * 2005-12-01 2007-06-21 Gifu Univ プロリン類縁体
WO2007065634A1 (fr) * 2005-12-07 2007-06-14 Ucb Pharma, S.A. Derives de la 3-carboxy-2-0x0-1-pyrrolidine et leurs utilisations
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
LV13630B (en) * 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
BRPI0712325A2 (pt) * 2006-06-08 2012-01-10 Ucb Pharma Sa processo para a preparação de co-cristais de pirrolidinonas, co-cristal, composição farmacêutica, e, uso de um co-cristal
KR101518427B1 (ko) 2006-06-15 2015-05-08 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
WO2008021666A2 (fr) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Compositions stables de lévétiracétam et procédés
KR101181194B1 (ko) * 2006-10-18 2012-09-18 화이자 프로덕츠 인코포레이티드 바이아릴 에터 우레아 화합물
WO2008103319A2 (fr) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Composés et procédés destinés à être utilisés dans la détection de la gabapentine
WO2008132139A2 (fr) * 2007-04-27 2008-11-06 Ucb Pharma S.A. Nouveaux dérivés hétérocycliques utiles pour le traitement des troubles du système nerveux central
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
CA2715685C (fr) * 2008-03-03 2015-04-28 Eric Schenkel Solutions pharmaceutiques, procede de preparation et utilisations therapeutiques
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US20110212944A1 (en) * 2008-07-01 2011-09-01 Julie Liu 2-oxo-1-pyrrolidine derivatives
EP2147911A1 (fr) 2008-07-24 2010-01-27 ZaCh System S.p.A. Procédé de préparation de lévétiracetam
JP4644881B2 (ja) * 2008-09-19 2011-03-09 高砂香料工業株式会社 ルテニウム錯体の製造方法
CN102227217A (zh) 2008-10-16 2011-10-26 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
US8168756B2 (en) 2008-10-24 2012-05-01 Ark Diagnostics, Inc. Levetiracetam immunoassays
EP2341777B1 (fr) * 2008-11-07 2015-01-21 NovaBay Pharmaceuticals, Inc. Compositions antimicrobiennes d'oxazolidinone, d'hydantoïne et d'imidazolidinone
ES2602606T3 (es) * 2008-11-18 2017-02-21 Ucb Biopharma Sprl Formulaciones de liberación prolongada que comprenden un derivado de 2-oxo-1-pirrolidina
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 지연 방출형 제형
FR2939311A1 (fr) * 2008-12-08 2010-06-11 Oreal Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
US8563036B2 (en) 2009-02-09 2013-10-22 Ucb Pharma, S.A. Pharmaceutical compositions comprising Brivaracetam
US8846411B2 (en) * 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
US20120171125A1 (en) 2009-08-07 2012-07-05 Ucb Pharma, S.A. Methods for Enhancing the Cognitive Function
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
US8487591B1 (en) 2009-12-31 2013-07-16 Cirrus Logic, Inc. Power control system with power drop out immunity and uncompromised startup time
SI2491045T1 (sl) 2009-10-23 2016-04-29 Ucb Biopharma Sprl 2-okso-1-pirolidinil imidazotiadiazolni derivati
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
EP2533645B1 (fr) 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
FR2961099B1 (fr) 2010-06-09 2012-06-15 Oreal Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
FR2961098A1 (fr) 2010-06-09 2011-12-16 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
FR2961101B1 (fr) 2010-06-09 2013-01-25 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
US8866452B1 (en) 2010-08-11 2014-10-21 Cirrus Logic, Inc. Variable minimum input voltage based switching in an electronic power control system
US9510401B1 (en) 2010-08-24 2016-11-29 Cirrus Logic, Inc. Reduced standby power in an electronic power control system
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
CA2818025A1 (fr) 2010-11-15 2012-05-24 Agenebio, Inc. Derives de pyridazine, compositions et methodes de traitement d'une deficience cognitive
US20120214859A1 (en) * 2011-02-09 2012-08-23 Michela Gallagher Methods and compositions for improving cognitive function
ME02351B (fr) 2011-04-18 2016-06-20 Ucb Biopharma Sprl Dérivés de 2-oxo-1-imidazolidinyl imidazothiadiazole
CN103636109B (zh) 2011-06-03 2016-08-17 塞瑞斯逻辑公司 用于操作开关电力转换器的方法和装置以及电力分配系统
IN2014CN03043A (fr) 2011-09-30 2015-07-03 Univ Tufts
WO2013100568A1 (fr) * 2011-12-27 2013-07-04 Bio-Pharm Solutions Co., Ltd. Composés carbamate de phényle destinés à prévenir ou à traiter l'avc
TW201408293A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
CA2885369A1 (fr) 2012-09-28 2014-04-03 Tufts University Derives d'uridine diphosphate, promedicaments, compositions et utilisations de ceux-ci
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
WO2014087367A2 (fr) * 2012-12-09 2014-06-12 Mahesh Kandula Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées
EP2945942B1 (fr) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Immunodosages de viroconazole
ES2674704T3 (es) 2013-02-13 2018-07-03 Ark Diagnostics, Inc. Inmunoensayos de posaconazol
CA2904180C (fr) 2013-03-13 2022-05-10 Tufts University Derives d'uridine nucleoside, compositions et procedes d'utilisation
AR095442A1 (es) 2013-03-13 2015-10-14 Univ Tufts Derivados de nucleósido de uridina, composiciones y métodos de uso
EP2968237A4 (fr) 2013-03-15 2016-08-31 Univ Johns Hopkins Procédés et compositions pour améliorer la fonction cognitive
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
JP6465634B2 (ja) * 2013-12-05 2019-02-06 株式会社日本触媒 環状アミド基含有重合体
JP6453632B2 (ja) * 2013-12-05 2019-01-16 株式会社日本触媒 環状アミドアクリレート含有組成物およびその製造方法
EP3083569B1 (fr) 2013-12-20 2022-01-26 Agenebio, Inc. Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive
ME03518B (fr) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
WO2015110435A1 (fr) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinaisons comprenant des modulateurs allostériques positifs ou des agonistes orthostériques de sous-type 2 de récepteur glutamatergique métabotrope, et leur utilisation
CN104098497B (zh) * 2014-06-17 2016-04-13 王庚禹 一种新的酰胺类化合物
WO2016075082A1 (fr) 2014-11-10 2016-05-19 Sandoz Ag Amination réductrice stéréosélective d'aldéhydes alpha-chiraux au moyen d'ω-transaminases pour la synthèse de précurseurs de la prégabaline et du brivaracétam
US20180021307A1 (en) 2015-02-20 2018-01-25 Ucb Biopharma Sprl Combination Treatment
WO2016191435A1 (fr) * 2015-05-25 2016-12-01 Peng Wang Procédés de production du brivaracetam
CN108689968B (zh) * 2015-05-25 2020-09-15 苏州鹏旭医药科技有限公司 两种化合物及其制备方法和在合成布瓦西坦中的用途
CN106365986B (zh) * 2015-07-21 2019-01-08 苏州鹏旭医药科技有限公司 化合物及其制备方法和在合成布瓦西坦中的用途
CN107922457B (zh) 2015-06-19 2022-05-13 森托瑞恩生物制药公司 用于控制药物释放的递送系统
WO2016205739A1 (fr) 2015-06-19 2016-12-22 Belew Mekonnen Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
WO2017076737A1 (fr) 2015-11-03 2017-05-11 Ucb Biopharma Sprl Procédé continu de préparation de brivaracétam
SI3371150T1 (sl) 2015-11-03 2021-11-30 UCB Biopharma SRL Postopek za pripravo brivaracetama
CN106748748B (zh) * 2015-11-10 2021-08-24 成都国为生物医药有限公司 一种布瓦西坦的制备方法及其中间体
EP3397253A1 (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
CN105646319B (zh) * 2015-12-30 2018-05-18 佛山市隆信医药科技有限公司 一种布瓦西坦的制备方法
EP3452447A4 (fr) 2016-05-03 2019-12-18 The Regents of The University of California Inhibiteurs de synthèse de protéines médiée par des ires
RU2629117C1 (ru) * 2016-06-14 2017-08-24 Сизов Владимир Владимирович Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
CN107513031B (zh) * 2016-06-16 2022-08-02 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2018210393A1 (en) 2017-01-20 2019-07-25 The Regents Of The University Of California Inhibitors of the N-terminal domain of the androgen receptor
WO2018141276A1 (fr) * 2017-02-05 2018-08-09 苏州鹏旭医药科技有限公司 Forme cristalline a de l'intermédiaire de brivaracétam et son procédé de préparation, forme cristalline c de brivaracétam et son procédé de préparation
CN106866483A (zh) * 2017-02-05 2017-06-20 苏州鹏旭医药科技有限公司 布瓦西坦的晶型c及其制备方法
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN108658831B (zh) * 2017-03-30 2021-11-05 江苏豪森药业集团有限公司 2-氧代-1-吡咯烷衍生物或其盐的制备方法
EP3615513B1 (fr) 2017-04-24 2022-07-20 Tesaro, Inc. Procédés de fabrication de niraparib
JP7221227B2 (ja) 2017-06-30 2023-02-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発毛を調節するための組成物及び方法
CN107793342A (zh) * 2017-10-19 2018-03-13 丽珠集团新北江制药股份有限公司 一种布瓦西坦的制备方法
CN107721896A (zh) * 2017-10-19 2018-02-23 丽珠集团新北江制药股份有限公司 一种布瓦西坦的中间体的制备方法
MX2020005472A (es) 2017-11-30 2020-11-11 Centurion Biopharma Corp Sistemas de administración de fármacos a base de maitansinoide.
CN111712511B (zh) 2017-11-30 2024-07-16 拉德克斯公司 澳瑞他汀e衍生物的白蛋白结合产物
WO2019152536A1 (fr) 2018-01-30 2019-08-08 The Regents Of The University Of California Inhibiteurs de la voie wnt/bêta-caténine
CN108147988B (zh) * 2018-02-13 2020-10-02 扬州奥锐特药业有限公司 一种高手性纯度内酰胺化合物的制备方法
CN108530402B (zh) * 2018-04-10 2020-06-26 浙江工业大学 一种(R)-3-丙基-γ-丁内酯的制备方法
EP3566760A1 (fr) * 2018-05-07 2019-11-13 Universite Libre De Bruxelles Procédé pour la nucléation de cristaux dans un tube capillaire à partir d'une solution
ES2947618T3 (es) 2018-05-08 2023-08-14 UCB Biopharma SRL Derivados de 1-imidazotiadiazolo-2H-pirrol-5-ona
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN110615744B (zh) * 2018-06-20 2023-01-06 上海朴颐化学科技有限公司 一种布瓦西坦中间体及其制备方法
WO2020006489A1 (fr) 2018-06-29 2020-01-02 The Regents Of The University Of California Nouvelles pinces moléculaires contre des troubles neurologiques et des infections virales
RU2699669C1 (ru) * 2018-07-04 2019-09-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы N-карбамоилметил-4-фенил-2-пирролидона
SG11202100429TA (en) 2018-07-27 2021-02-25 California Inst Of Techn Cdk inhibitors and uses thereof
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
US20220047548A1 (en) 2018-12-04 2022-02-17 Metys Pharmaceuticals AG SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO
CN109932442A (zh) * 2019-03-04 2019-06-25 成都美域高制药有限公司 一种布瓦西坦异构体的检测方法
WO2020198323A1 (fr) 2019-03-25 2020-10-01 California Institute Of Technology Inhibiteurs de prmt5 et leurs utilisations
SG11202112827QA (en) 2019-06-04 2021-12-30 Hager Biosciences Llc Imidazolo derivatives, compositions and methods as orexin antagonists
CN110357752A (zh) * 2019-08-15 2019-10-22 中国工程物理研究院化工材料研究所 一种快速制备均匀包覆含能材料的方法
RU2732245C1 (ru) * 2019-08-30 2020-09-14 Ооо "Валента-Интеллект" Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
CN110551050A (zh) * 2019-09-02 2019-12-10 南通大学 一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
US10781170B1 (en) 2019-10-21 2020-09-22 Divi's Laboratories Ltd. Process for preparing Brivaracetam
US20230100559A1 (en) 2020-01-07 2023-03-30 The Trustees Of Princeton University Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism
EP4087847A4 (fr) 2020-01-10 2024-02-28 The Regents of the University of California Compositions et méthodes de traitement de maladies neurodégénératives
US20230174460A1 (en) 2020-04-21 2023-06-08 President And Fellowes Of Harvard College Afmt analogs and their use in methods of treating parkinson's disease
LV15614A (lv) 2020-07-30 2022-02-20 Latvijas Organiskās Sintēzes Institūts 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
US20230265082A1 (en) 2020-08-10 2023-08-24 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
CA3191166A1 (fr) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. 3-amino-4-methylbenzenesulfonamides substitues en tant qu'inhibiteurs a petites molecules de la protease 28 specifique a l'ubiquitine
WO2022035806A1 (fr) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Inhibiteurs à petites molécules pyrimidine-thiéno-pyridine tricycliques fusionnées de la protéase 28 spécifique de l'ubiquitine
CN116323571A (zh) 2020-10-23 2023-06-23 丹娜法伯癌症研究院 肌酸激酶（ck）的共价抑制剂以及其用于治疗和预防癌症的用途
WO2022133237A2 (fr) 2020-12-18 2022-06-23 Cornell University Méthodes de traitement de troubles neurodégénératifs et de cancers liés à stat3 au moyen de suppresseurs de fuite d'électrons
WO2022140289A1 (fr) 2020-12-21 2022-06-30 Cornell University Système d'administration de médicaments à liaison peptidique
US20240132480A1 (en) 2021-01-08 2024-04-25 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
US11400074B1 (en) 2021-02-01 2022-08-02 Divi's Laboratories Ltd. Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
CN114948953A (zh) * 2021-06-29 2022-08-30 四川大学华西医院 一种杂原子取代芳香类化合物及其盐的用途
CN113511994B (zh) * 2021-08-16 2023-03-21 江苏八巨药业有限公司 一种左乙拉西坦的制备方法
CN114634437B (zh) * 2022-03-29 2023-05-30 武汉氟本氘合新材料科技有限公司 一种布瓦西坦的简易制备方法
US11884623B2 (en) 2022-05-23 2024-01-30 Divi's Laboratories Ltd. Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
WO2023250157A1 (fr) 2022-06-24 2023-12-28 Cornell University Inhibiteurs de mycobacterium tuberculosis lipoamide déshydrogénase
WO2024013209A1 (fr) 2022-07-13 2024-01-18 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procédés d'utilisation
WO2024039886A1 (fr) 2022-08-19 2024-02-22 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
WO2024049236A1 (fr) * 2022-08-31 2024-03-07 고려대학교 산학협력단 Dérivé de gamma lactame chiral ou sel pharmaceutiquement acceptable de celui-ci, et sa méthode de préparation
WO2024163711A1 (fr) 2023-02-02 2024-08-08 Osmoses Inc. Membranes composites polymères en échelle de norbornyl benzocyclobutène pour la séparation de fluides
EP4431086A1 (fr) 2023-03-16 2024-09-18 Adalvo Limited Composition pharmaceutique comprenant du (2s)-2--[(4r)-2-oxo-4-propyltétrahydro-1h-pyrrol-1-yl!butanamide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE92031C (fr)
DD92031A (fr) *
US2836599A (en) * 1957-03-07 1958-05-27 Aerojet General Co Nu-(carboxyalkyl) dinitro lactams
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
US4008281A (en) 1973-12-03 1977-02-15 Monsanto Company Asymmetric catalysis
HU177239B (hu) 1974-10-15 1981-08-28 Monsanto Co Eljárás N-acetamido-L-alanin-származékok előállítására α-acetamido-akrilsav-származékok aszimmetrikus katalitikus hídrogénezésével
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
CN1015542B (zh) * 1984-05-15 1992-02-19 尤西比公司 (R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
JPS60166692A (ja) 1984-09-28 1985-08-29 Kazuo Achinami 新規不斉還元試薬
CH666891A5 (de) * 1985-11-26 1988-08-31 Lonza Ag 4-alkoxy-2-oxo-pyrrolidin-1-yl-essigsaeure-c(1)-c(4)-alkylester, deren herstellung und verwendung.
DE3719873A1 (de) * 1987-06-13 1988-12-29 Basf Ag Verfahren zur herstellung von itaconsaeurediestern und itaconsaeure
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5171892A (en) 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
TW544311B (en) * 1998-08-06 2003-08-01 Daiichi Seiyaku Co Therapeutic or preventive agent for intractable epilepsies
CZ20001055A3 (cs) * 1998-10-02 2000-08-16 Dupont Pharmaceuticals Company Nové laktamové inhibitory metaloproteázy
ATE361751T1 (de) 1999-12-01 2007-06-15 Ucb Sa Ein pyrrolidinacetatderivat zur behandlung von chronischem oder neuropathischem schmerz
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same

Also Published As

Publication number Publication date
RU2006125756A (ru) 2008-01-27
HUP0204526A2 (hu) 2003-04-28
US20120035239A1 (en) 2012-02-09
JP2003523996A (ja) 2003-08-12
SI1265862T1 (sl) 2006-02-28
AU2001252144B2 (en) 2005-04-28
KR100681580B1 (ko) 2007-02-09
EP1263727A1 (fr) 2002-12-11
MXPA02008206A (es) 2004-04-05
HK1052516A1 (en) 2003-09-19
HK1052695B (zh) 2005-05-06
RU2005125569A (ru) 2007-02-20
CN1404470A (zh) 2003-03-19
IS7921A (is) 2005-06-29
IL150757A0 (en) 2003-02-12
EP1477478B1 (fr) 2010-11-17
NO2023025I1 (no) 2023-06-20
HU230270B1 (hu) 2015-11-30
ES2248307T3 (es) 2006-03-16
ATE304999T1 (de) 2005-10-15
DE60107216D1 (de) 2004-12-23
PL365159A1 (en) 2004-12-27
RU2002124865A (ru) 2004-01-10
RO121597B1 (ro) 2007-12-28
LU92993I2 (fr) 2016-05-11
BR0108657A (pt) 2003-04-29
IL166768A (en) 2010-04-15
ZA200205671B (en) 2003-11-10
WO2001064637A1 (fr) 2001-09-07
DE60119397D1 (de) 2006-06-08
WO2001062726A3 (fr) 2002-01-17
US7217826B2 (en) 2007-05-15
IS7919A (is) 2005-06-29
HUS1600017I1 (hu) 2020-02-28
IL170181A (en) 2010-11-30
NO20023995L (no) 2002-10-21
TW200626545A (en) 2006-08-01
US20040087646A1 (en) 2004-05-06
RU2291860C3 (ru) 2017-11-16
US20100222576A1 (en) 2010-09-02
BRPI0108664B1 (pt) 2016-07-26
AU2001252144C1 (en) 2008-03-20
BG107004A (bg) 2003-04-30
DE60113514T2 (de) 2006-05-18
YU63202A (sh) 2005-09-19
DE60113514D1 (de) 2005-10-27
EP1263727B1 (fr) 2004-11-17
HUP0204526A3 (en) 2005-03-29
CN1179944C (zh) 2004-12-15
DE60143493D1 (de) 2010-12-30
US6784197B2 (en) 2004-08-31
EP1265862B1 (fr) 2005-09-21
AU2005200717A1 (en) 2005-03-17
MEP6109A (en) 2011-12-20
PL213669B1 (pl) 2013-04-30
CO5280059A1 (es) 2003-05-30
ES2264060T3 (es) 2006-12-16
KR100759145B1 (ko) 2007-09-14
KR100720784B1 (ko) 2007-05-23
MY140593A (en) 2009-12-31
DE60119397T2 (de) 2007-04-19
NO20023997D0 (no) 2002-08-22
NO20023997L (no) 2002-10-22
CY1109718T1 (el) 2014-08-13
NO2016005I2 (no) 2016-03-08
IS7918A (is) 2005-06-29
RU2292336C2 (ru) 2007-01-27
JP4938259B2 (ja) 2012-05-23
MY127149A (en) 2006-11-30
KR20020075926A (ko) 2002-10-07
EP1447399B9 (fr) 2006-10-18
IL150842A0 (en) 2003-02-12
CN1680314A (zh) 2005-10-12
US8492416B2 (en) 2013-07-23
ATE325093T1 (de) 2006-06-15
EG24375A (en) 2009-03-19
NO2016005I1 (no) 2016-03-08
CY2016022I1 (el) 2016-10-05
EP1452524A1 (fr) 2004-09-01
BG65923B1 (bg) 2010-05-31
HK1052695A1 (en) 2003-09-26
CY2016022I2 (el) 2016-10-05
IS7922A (is) 2005-06-29
AU2005200717B2 (en) 2007-05-17
US6713635B2 (en) 2004-03-30
CA2401048A1 (fr) 2001-09-07
JP2006022107A (ja) 2006-01-26
JP4769756B2 (ja) 2011-09-07
BRPI0108664B8 (pt) 2021-05-25
BG65783B1 (bg) 2009-11-30
CA2401033A1 (fr) 2001-08-30
KR20050090090A (ko) 2005-09-12
AU2005200718A1 (en) 2005-03-17
KR20050091112A (ko) 2005-09-14
NO324485B1 (no) 2007-10-29
NZ520448A (en) 2004-03-26
PT1447399E (pt) 2006-09-29
AU7389601A (en) 2001-09-12
CU23293B7 (es) 2008-06-30
US20080097109A1 (en) 2008-04-24
HU229514B1 (en) 2014-01-28
AU778510B2 (en) 2004-12-09
BG65803B1 (bg) 2009-12-31
ATE445597T1 (de) 2009-10-15
SA01220027B1 (ar) 2006-09-19
DK1452524T3 (da) 2010-03-01
JP2006022108A (ja) 2006-01-26
CZ20022850A3 (cs) 2003-02-12
US20030040631A1 (en) 2003-02-27
RS50455B (sr) 2010-03-02
MXPA02008056A (es) 2004-08-12
RU2005125645A (ru) 2007-02-20
US7358276B2 (en) 2008-04-15
JP4121744B2 (ja) 2008-07-23
EP1447399B1 (fr) 2006-05-03
ES2334998T3 (es) 2010-03-18
ES2231501T3 (es) 2005-05-16
IL150842A (en) 2008-06-05
BR0108664A (pt) 2003-04-29
NO324051B1 (no) 2007-08-06
CZ304420B6 (cs) 2014-04-30
NO20053645L (no) 2002-10-22
ZA200205837B (en) 2003-11-04
KR100816185B1 (ko) 2008-03-21
IS2754B (is) 2011-09-15
IS2119B (is) 2006-06-15
HK1052516B (zh) 2006-02-10
PT1452524E (pt) 2010-01-18
PL359388A1 (en) 2004-08-23
PL212197B1 (pl) 2012-08-31
EP1477478A2 (fr) 2004-11-17
SA01220078B1 (ar) 2006-10-29
KR20020075927A (ko) 2002-10-07
CZ20022849A3 (cs) 2003-02-12
IS6481A (is) 2002-07-23
US20050171187A1 (en) 2005-08-04
US20030120080A1 (en) 2003-06-26
RU2291860C2 (ru) 2007-01-20
RO121559B1 (ro) 2007-11-30
WO2001062726A2 (fr) 2001-08-30
US7692028B2 (en) 2010-04-06
EP1577296A1 (fr) 2005-09-21
ATE282592T1 (de) 2004-12-15
NO20023995D0 (no) 2002-08-22
CN1740150A (zh) 2006-03-01
CN1208319C (zh) 2005-06-29
ATE488500T1 (de) 2010-12-15
BE2016C012I2 (fr) 2020-01-30
CZ304702B6 (cs) 2014-09-03
NO20053644L (no) 2002-10-22
CA2401048C (fr) 2009-01-20
PL210121B1 (pl) 2011-12-30
JP2007182459A (ja) 2007-07-19
EP1265862A2 (fr) 2002-12-18
IS2176B (is) 2006-12-15
CY1105517T1 (el) 2010-07-28
CU23201A3 (es) 2007-04-06
FR16C1001I2 (fr) 2017-02-03
DK1265862T3 (da) 2006-01-30
HUP0300196A2 (hu) 2003-06-28
CN1404469A (zh) 2003-03-19
CO5271667A1 (es) 2003-04-30
DK1447399T3 (da) 2006-08-28
ME00595B (fr) 2011-12-20
IL166768A0 (en) 2006-01-15
US20040192757A1 (en) 2004-09-30
BG109297A (en) 2006-06-30
JP4081275B2 (ja) 2008-04-23
GB0004297D0 (en) 2000-04-12
MY139420A (en) 2009-09-30
IS7923A (is) 2005-06-29
EP1477478A3 (fr) 2004-11-24
US20040092576A1 (en) 2004-05-13
CA2401033C (fr) 2008-07-29
IS7920A (is) 2005-06-29
HUP0300196A3 (en) 2005-10-28
ES2355140T3 (es) 2011-03-23
TW200626544A (en) 2006-08-01
DE60107216T2 (de) 2005-11-03
EP1447399A1 (fr) 2004-08-18
RU2355680C2 (ru) 2009-05-20
US6806287B2 (en) 2004-10-19
HU0500902D0 (en) 2005-12-28
EP1577295A1 (fr) 2005-09-21
LTPA2016013I1 (lt) 2016-05-25
US20050171188A1 (en) 2005-08-04
RS50454B (sr) 2010-03-02
AU5214401A (en) 2001-09-03
US6911461B2 (en) 2005-06-28
CN1740151A (zh) 2006-03-01
CN1303066C (zh) 2007-03-07
EP1452524B1 (fr) 2009-10-14
DE60140222D1 (de) 2009-11-26
JP2003528828A (ja) 2003-09-30
US6969770B2 (en) 2005-11-29
EP1604979A1 (fr) 2005-12-14
LTC1265862I2 (lt) 2023-09-11
AU2005200718B2 (en) 2007-05-24
MY138966A (en) 2009-08-28
US20040116507A1 (en) 2004-06-17
US20050159475A1 (en) 2005-07-21
BG107016A (en) 2003-04-30
IS6472A (is) 2002-07-16
YU63102A (sh) 2005-09-19
NL300815I2 (fr) 2016-07-27
US6858740B2 (en) 2005-02-22
US8034958B2 (en) 2011-10-11

Similar Documents

Publication Publication Date Title
FR16C1001I1 (fr) "Dérivé de 2-oxo-1-pyrrolidine et ses applications pharmaceutique"